The FDA has accepted Rybrevant Faspro (amivantamab and hyaluronidase-lpuj) as the primary and solely subcutaneous, chemo-free therapy for sufferers with EGFR-mutated non-small cell lung most...
Lively Biotech has obtained optimistic suggestions from regulators on a protocol modification to its ongoing proof-of-concept scientific trial evaluating tasquinimod in sufferers with myelofibrosis, a...
Receiving a prognosis of anal most cancers can really feel overwhelming, however understanding the illness is step one towards efficient administration and...
Dr. Vikram C. Gorantla, a medical oncologist at College of Pittsburgh Medical Middle, discusses key issues for sufferers with mind metastases resulting...
The U.S. Meals and Drug Administration (FDA) has granted accelerated approval to the CD20xCD3 bispecific antibody Lunsumio VELO (mosunetuzumab), as a subcutaneous...
